About this Research Topic
The process of getting a new drug to market involves a long drawn out process of research and testing, costing millions in the process, and ultimately nothing is promised when trying to identify new therapeutic compounds. By discovering that already licensed medication readily available in the market have effects on diseases otherwise not knowingly attributed to these drug molecules avoids this research process and can get new potentially life saving treatments to patients much more quickly. This method of drug discovery also alleviates the costly drug testing measures now commonplace in the pharmaceutical industry, which means these savings can be passed on to healthcare services, freeing up funds for other patient services, or minimizing the strain on less economically affluent cancer care teams.
Chemotherapy, radiotherapy, immunotherapy and other traditional cancer interventions are often very expensive to produce and can be difficult to procure, and are famous for their unpleasant side effects. Cancer treatments are also commonly very specific to the type of causative cancer, and don’t regularly have efficacy across multiple tumor types or sites. For this reason, finding new indications for established, well palatable medications in treating cancer, or supplementing cancer treatment can lead to new breakthroughs in the curing of the disease, or in making treatment more palatable and manageable for patients.
This research topic aims to present findings from the scientific community finding new ways of using already marketed and licensed medications in new ways to benefit cancer patients.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Reposition drugs within an oncological context
- Combining chemotherapy to have innovative options to treat various carcinoma
- Use of vitamins to supplement cancer care
- New combination therapy options in various cancers
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Chemotherapy, radiotherapy, immunotherapy and other traditional cancer interventions are often very expensive to produce and can be difficult to procure, and are famous for their unpleasant side effects. Cancer treatments are also commonly very specific to the type of causative cancer, and don’t regularly have efficacy across multiple tumor types or sites. For this reason, finding new indications for established, well palatable medications in treating cancer, or supplementing cancer treatment can lead to new breakthroughs in the curing of the disease, or in making treatment more palatable and manageable for patients.
This research topic aims to present findings from the scientific community finding new ways of using already marketed and licensed medications in new ways to benefit cancer patients.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Reposition drugs within an oncological context
- Combining chemotherapy to have innovative options to treat various carcinoma
- Use of vitamins to supplement cancer care
- New combination therapy options in various cancers
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: cancer, medication, drugs, unlicensed, indication, combination
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
